Screener
Ligand Pharmaceuticals LGND Tolerance Therapeutics (Tzield®) — Financial Royalty Assets, Allowance
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Qarziba | $101,303 | $(468) | $100,835 | $118,593 | $(498) | $118,095 |
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported tolerance therapeutics (tzield®) — financial royalty assets, allowance of $99K in Q2 2026.
- What does tolerance therapeutics (tzield®) — financial royalty assets, allowance mean?
- This metric represents the cumulative valuation adjustments, such as allowances for credit losses or impairment charges, applied to the gross carrying value of the Tzield royalty asset. It reflects management's assessment of potential risks or collectability issues regarding future royalty payments. A significant increase in this allowance may signal deteriorating expectations for the underlying product's commercial performance.
Ask your AI about Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, allowance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude